Bridging the preclinical-clinical boundary

The preclinical-clinical boundary is a key checkpoint in the translational pathway for research. It refers to the point at which preclinical evidence is considered sufficient to merit the move to first-in-human clinical studies, and represents a significant escalation in both resourcing and time, with a high risk of failure. Therefore there is a drive to ensure that the evidence base for progression into clinical studies is as robust and predictive as possible to maximise the chances of success and minimise risk of failure.

Status: Completed

AMS response to the Next Generation Researchers Initiative

In response to a request from the US National Academy of Sciences, the Academy produced a paper providing a UK snapshot of efforts by the research community to aid the transition to independent research careers for biomedical researchers. The Academy's paper was published in May 2018. 

Status:

Higher Education and Research Bill

Status: Ongoing

Science Communication inquiry

Status: Completed

Consultation on Tier 2 immigration visas

Status: Ongoing

General Medical Council academic training review

The Academy responded to the General Medical Council's academic training review

Status: Completed

Shape of Training

Academy activity related to recommendations for changes to postgraduate medical training

Status: Ongoing

Systems biology

In 2005 the Academy of Medical Sciences and the Royal Academy of Engineering identified systems biology as an area of scientific and national priority and set up a joint working group to investigate. The report of this working group was released in 2007.

Status: Completed

Revalidation reforms

Status: Completed

Strengthening clinical research

Status: Completed